Interventional Retrospective Case Series of Patients Undergoing Treatment Intervals of More Than Twenty‐Four (24) Weeks With Faricimab

<b>Purpose:</b> The aim of this study is to evaluate the efficacy and safety of intravitreal faricimab dosing interval at and beyond 24 weeks in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). <b>Methods:</b> This study is a retrospective case series of eight patients with persistent DME and nAMD who received intravitreal faricimab at and beyond the 24-week (6-month) dosing interval regimen. <b>Results:</b> The majority of patients experienced an improved mean best-corrected visual acuity (BCVA) of 9.9 letters; congruent anatomical improvement (mean central macular thickness (CMT)) decrease of 44 <i>μ</i>m on optical coherence tomography (OCT) is demonstrated at 6 months despite extended faricimab dosing intervals. <b>Conclusions:</b> Extended intravitreal faricimab dosing intervals at and beyond 24 weeks maintained visual and anatomical outcomes in patients over 1 year. This suggests the feasibility of personalized extended dosing tailored to each patient's disease activity, potentially reducing treatment burden.